Search

Your search keyword '"Caldarola, Giacomo"' showing total 294 results
Start Over Author "Caldarola, Giacomo"
294 results on '"Caldarola, Giacomo"'

1. Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment

Author

Caldarola, Giacomo, primary, Pinto, Lorenzo Maria, additional, Bellinato, Francesco, additional, Bernardini, Nicoletta, additional, Campione, Elena, additional, Chiricozzi, Andrea, additional, Colonna, Laura, additional, De Simone, Clara, additional, Diluvio, Laura, additional, Gisondi, Paolo, additional, Matteini, Enrico, additional, Tomassetti, Eleonora, additional, Tolino, Ersilia, additional, Bianchi, Luca, additional, and Peris, Ketty, additional

Published
2024
Full Text
View/download PDF

2. Italian National Registry of Alopecia Areata: an epidemiological study of 699 Italian patients

Author

PIRACCINI, Bianca Maria, primary, RAPPARINI, Luca, additional, QUADRELLI, Federico, additional, ALESSANDRINI, Aurora, additional, BRUNI, Francesca, additional, CEDIRIAN, Stephano, additional, PAMPALONI, Francesca, additional, MARCELLI, Emanuela, additional, BORTOLANI, Barbara, additional, GIAMPIERI, Enrico, additional, GALLO, Giuseppe, additional, TORRELLI, Francesca, additional, SCIAMARRELLI, Nadia, additional, QUAGLINO, Pietro, additional, TOMASINI, Carlo, additional, BARRUSCOTTI, Stefania, additional, AMBROGIO, Francesca, additional, FOTI, Caterina, additional, PICCIALLO, Michele, additional, CARO, Gemma, additional, ROSSI, Alfredo, additional, PELLACANI, Giovanni, additional, ALA, Lorenzo, additional, ACRI, Maria Cristina, additional, DILUVIO, Laura, additional, MATTEINI, Enrico, additional, BIANCHI, Luca, additional, ARGENZIANO, Giuseppe, additional, BABINO, Graziella, additional, FULGIONE, Elisabetta, additional, GNESOTTO, Laura, additional, SECHI, Andrea, additional, NALDI, Luigi, additional, TASSONE, Francesco, additional, PERIS, Ketty, additional, CALDAROLA, Giacomo, additional, CAPOSIENA CARO, Raffaele Dante, additional, BAZZACCO, Giulia, additional, ZALAUDEK, Iris, additional, VASTARELLA, Maria, additional, CANTELLI, Mariateresa, additional, PATRÌ, Angela, additional, DALL’OGLIO, Federica, additional, LACARRUBBA, Francesco, additional, MICALI, Giuseppe, additional, FRAGHÌ, Alessandro, additional, BOCCALETTI, Valeria, additional, MARZANO, Angelo Valerio, additional, BARBARESCHI, Mauro, additional, SILVIO, Martina, additional, VAGNOZZI, Emanuele, additional, FARGNOLI, Maria Concetta, additional, CAPONIO, Chiara, additional, ATZORI, Laura, additional, SANNA, Silvia, additional, ANEDDA, Jasmine, additional, FELICIANI, Claudio, additional, DE FELICI DEL GIUDICE, Maria Beatrice, additional, SCANDAGLI, Ilaria, additional, PRIGNANO, Francesca, additional, RONGIOLETTI, Franco, additional, PODO BRUNETTI, Antonio, additional, BIGOTTO, Gianmarco D., additional, OFFIDANI, Anna Maria, additional, SIMONETTI, Oriana, additional, LEMBO, Serena, additional, RAIMONDO, Annunziata, additional, BALESTRI, Riccardo, additional, IORIS, Tommaso, additional, GISONDI, Paolo, additional, BELLINATO, Francesco, additional, TROVATO, Emanuele, additional, CINOTTI, Elisa, additional, PAPINI, Manuela, additional, CICOLETTI, Michela, additional, CORAZZA, Monica, additional, and STARACE, Michela, additional

Published
2024
Full Text
View/download PDF

3. Clinical, epidemiological, and therapeutic hallmarks of pyoderma gangrenosum: a case series of 35 patients.

Author

Caldarola, Giacomo, Traini, Daniele O., Falco, Gennaro M., Chiricozzi, Andrea, De Luca, Eleonora, Mannino, Maria, Pellegrino, Luca, Peris, Ketty, and De Simone, Clara

Abstract

Background: Over the past few decades, advances in medical research and diagnostic tools have shed light on some aspects of pyoderma gangrenosum (PG). Nevertheless, the multifactorial etiology, pathogenesis, and optimal management strategies for PG need to be further investigated. To address these knowledge gaps and contribute to a better understanding of this complex dermatological disorder, we collected epidemiological, clinical, and therapeutic aspects of a case series of PG patients occurring in our department over the past 10 years. Methods: We performed a single‐centered, retrospective, observational study analyzing all cases with a diagnosis of PG observed at the Dermatology clinic of the Fondazione Policlinico A. Gemelli IRCCS Catholic University from January 1, 2013, to January 1, 2023. For each case, we retrieved demographic data, the presence of other skin and systemic conditions, and the histopathological and clinical characteristics of PG, such as clinical variant, number of lesions, disease localization, previous therapy, response to treatment, and occurrence of relapse. Results: We included 35 patients, 22 females and 13 males with a mean age of 40.0 years. Twenty patients (57.1%) had multiple localizations of disease, and the most commonly involved site was the lower limbs (85.7%). The lesions were mainly associated with inflammatory bowel diseases (51.4%) and hidradenitis suppurativa (37.1%). Clinical resolution with complete re‐epithelialization was achieved in 25 patients (71.4%) with an average time of 20.8 months. On average, patients who underwent therapy with biological drugs had better outcomes. Conclusions: PG is a severe, rare, and pleomorphic disease associated with a broad spectrum of conditions. Corticosteroids remain the primary first‐line approach for severe forms, but using biological immunosuppressants is promising. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Assessing a measure for Quality of Life in patients with severe Alopecia Areata: a multicentric Italian study.

Author

Caldarola, Giacomo, Raimondi, Giulia, Samela, Tonia, Pinto, Lorenzo, Pampaloni, Francesca, Rita Starace, Michela Valeria, Diluvio, Laura, Dall'Oglio, Federica, Vagnozzi, Emanuele, de Felici del Giudice, Maria Beatrice, Balestri, Riccardo, Ambrogio, Francesca, Girolomoni, Giampiero, Riva, Silvia Francesca, Moro, Francesco, Atzori, Laura, Gallo, Giuseppe, Ribero, Simone, Simonetti, Oriana, and Barruscotti, Stefania

Published
2024
Full Text
View/download PDF

5. Evaluation of the Impact of Night Shift Work on Disease Severity in Psoriatic Patients: A Case-Control Study with Clinical, Hormonal, and Immunological Evaluation.

Author

Caldarola, Giacomo, De Luca, Eleonora, Barini, Angelina, Basile, Umberto, Carnazzo, Valeria, Chiricozzi, Andrea, Tolusso, Barbara, Gremese, Elisa, Di Nardo, Lucia, Peris, Ketty, and De Simone, Clara

Subjects
SHIFT systems, NIGHT work, CIRCADIAN rhythms, CASE-control method, BLOOD sampling
Abstract

Introduction: Night shift work disrupts circadian rhythms and has been associated with immune system alterations and various health conditions. However, there is limited data regarding its impact on psoriasis. The aim of our study was to compare psoriasis severity and the hormonal and immunological profile in patients with a night shift work to those with a daytime occupation. Methods: In this case-control study, we enrolled psoriatic patients aged >18 years engaged in night shift work and a control group of psoriatic patients with a daytime occupation. A further categorization was performed by the duration of night shift work: < or ≥7 days a month and < or ≥8 years. Disease severity was evaluated by PASI, BSA, and DLQI, and blood samples were taken to measure various hormonal and immunological markers. Univariable and multivariable analysis were performed to assess differences between the two groups. Results: A total of 40 night shift workers were included, along with 36 patients in the control group. Patients who worked night shifts at least 7 days a month had significantly higher PASI scores (11.2 ± 6.6 vs. 8.5 ± 6.6; p = 0.04) and higher IL-8 serum (115.33 ± 463.65 pg/mL vs. 19.98 ± 29.78 pg/mL; p = 0.006) compared to patients who did not. Night shifts workers for at least 8 years had higher BMI (28.65 ± 4.56 vs. 25.32 ± 5.50, p = 0.010), and females had higher testosterone levels (0.46 ± 0.53 ng/mL vs. 0.23 ± 0.13 ng/mL; p = 0.055). Conclusion: Night shift might increase psoriasis severity and have an impact on chronic inflammation, obesity, and hormonal imbalances. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study)

Author

Orsini, Diego, primary, Caldarola, Giacomo, additional, Dattola, Annunziata, additional, Campione, Elena, additional, Bernardini, Nicoletta, additional, Frascione, Pasquale, additional, De Simone, Clara, additional, Richetta, Antonio G., additional, Galluzzo, Marco, additional, Skroza, Nevena, additional, Assorgi, Chiara, additional, Amore, Emanuele, additional, Falco, Gennaro M., additional, Gaeta Shumak, Ruslana, additional, Artosi, Fabio, additional, Maretti, Giulia, additional, Potenza, Concetta, additional, Bianchi, Luca, additional, Pellacani, Giovanni, additional, Peris, Ketty, additional, Bonifati, Claudio, additional, and Graceffa, Dario, additional

Published
2024
Full Text
View/download PDF

9. Awareness of obesity among patients with psoriasis

Author

Bellinato, Francesco, primary, Gisondi, Paolo, additional, Balato, Anna, additional, Caldarola, Giacomo, additional, Cammarata, Edoardo, additional, Campione, Elena, additional, Carugno, Andrea, additional, Conti, Andrea, additional, Corazza, Monica, additional, Dapavo, Paolo, additional, Dattola, Annunziata, additional, Di Lernia, Vito, additional, Gasperini, Massimo, additional, Panduri, Salvatore, additional, Prignano, Francesca, additional, Satolli, Francesca, additional, Spisni, Enzo, additional, and Girolomoni, Giampiero, additional

Published
2023
Full Text
View/download PDF

15. Drug survival of biologics and non‐biologics in patients affected by palmoplantar psoriasis: a "real‐world", mono‐center experience.

Author

Caldarola, Giacomo, Falco, Gennaro Marco, Calabrese, Laura, D'Amore, Alessandra, Chiricozzi, Andrea, Mariani, Marco, Palmisano, Gerardo, De Simone, Clara, and Peris, Ketty

Subjects
*TERMINATION of treatment, *BIOLOGICALS, *PSORIASIS, *DEMOGRAPHIC characteristics, *MULTIVARIATE analysis, *PALMOPLANTAR keratoderma
Abstract

Background: Data on the treatment of palmoplantar psoriasis (PP) are very limited as these patients are often excluded from clinical trials. Moreover, this form of psoriasis is often resistant to treatment, making its clinical management complex. Methods: Primary endpoint was to evaluate the clinical and demographic characteristics and the drug survival of both biological and non‐biological drugs in a population affected by PP. Secondary endpoint was to highlight any differences between the hyperkeratotic and pustular variant. We analyzed data from 233 psoriasis patients with palmoplantar involvement, with or without chronic plaque psoriasis. We performed a drug‐survival analysis with the aid of Kaplan‐Meier survival and a multivariate analysis to highlight the influence of certain variables on treatment persistence using a Cox regression model. Results: The drug‐survival analysis revealed that biologic drugs compared to non‐biologic drugs are associated with a higher persistence in treatment (59.73 vs. 43.56%); in particular, anti‐IL23 drugs were found to be the drugs with the best drug‐survival overall (67.94% of patients at 60 months are still on these drugs). Furthermore, our multivariate analysis shows that when compared with biological drugs, non‐biological drugs are associated with an increased risk of treatment discontinuation (HR = 1.95 [95% CI: 1.41–2.68], P = 0.001). Conclusions: Our study confirms the difficulty of treating PP and shows that biologic drugs are associated with longer persistence in treatment than non‐biologics in both PP's variants, not because of their higher effectiveness but because of their better safety profile. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. 2-Year Experience with Risankizumab in the Treatment of Plaque Psoriasis in Lazio Region, Italy

Author

Caldarola, Giacomo, primary, De Luca, Eleonora, additional, Bavetta, Mauro, additional, Bernardini, Nicoletta, additional, Dattola, Annunziata, additional, De Simone, Clara, additional, Graceffa, Dario, additional, Bonifati, Claudio, additional, Tribuzi, Paola, additional, Giordano, Domenico, additional, Mariani, Marco, additional, Moretta, Gaia, additional, Pagnanelli, Gianluca, additional, Panasiti, Vincenzo, additional, Provini, Alessia, additional, Richetta, Antonio, additional, Zangrilli, Arianna, additional, Bianchi, Luca, additional, Pellacani, Giovanni, additional, and Peris, Ketty, additional

Published
2023
Full Text
View/download PDF

18. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)

Author

Gargiulo, Luigi, primary, Narcisi, Alessandra, additional, Ibba, Luciano, additional, Balato, Anna, additional, Bianchi, Luca, additional, Brianti, Pina, additional, Buononato, Dario, additional, Burlando, Martina, additional, Caldarola, Giacomo, additional, Campanati, Anna, additional, Campione, Elena, additional, Carrera, Carlo G., additional, Carugno, Andrea, additional, Cristaudo, Antonio, additional, Cusano, Francesco, additional, Dapavo, Paolo, additional, Dattola, Annunziata, additional, De Simone, Clara, additional, Gaiani, Francesca M., additional, Gisondi, Paolo, additional, Giunta, Alessandro, additional, Loconsole, Francesco, additional, Maione, Vincenzo, additional, Mortato, Edoardo, additional, Marzano, Angelo V., additional, Maurelli, Martina, additional, Megna, Matteo, additional, Mercuri, Santo R., additional, Offidani, Annamaria, additional, Orsini, Diego, additional, Parodi, Aurora, additional, Pellacani, Giovanni, additional, Potestio, Luca, additional, Quaglino, Pietro, additional, Richetta, Antonio G., additional, Romano, Francesca, additional, Sena, Paolo, additional, Venturini, Marina, additional, Malagoli, Piergiorgio, additional, and Costanzo, Antonio, additional

Published
2023
Full Text
View/download PDF

21. Awareness of obesity among patients with psoriasis.

Author

Bellinato, Francesco, Gisondi, Paolo, Balato, Anna, Caldarola, Giacomo, Cammarata, Edoardo, Campione, Elena, Carugno, Andrea, Conti, Andrea, Corazza, Monica, Dapavo, Paolo, Dattola, Annunziata, Di Lernia, Vito, Gasperini, Massimo, Panduri, Salvatore, Prignano, Francesca, Satolli, Francesca, Spisni, Enzo, and Girolomoni, Giampiero

Subjects
OBESITY, PSORIASIS, PSORIATIC arthritis, LOW-calorie diet, WEIGHT loss, BODY weight
Abstract

A study published in the Journal of the European Academy of Dermatology & Venereology examined the awareness of obesity among patients with psoriasis. The study found that while most participants were aware of the negative effects of obesity on their general health, fewer were aware of its impact on psoriasis severity and response to treatment. However, the majority of patients expressed a desire to lose weight, with obese patients being more motivated than overweight patients. The findings suggest that there is a strong motivation among individuals with psoriasis to address their weight and improve their overall health. [Extracted from the article]

Published
2024
Full Text
View/download PDF

26. Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study

Author

Chiricozzi, Andrea, Dal Bello, Giacomo, Gori, Niccolò, Di Nardo, Lucia, Schena, Donatella, Caldarola, Giacomo, Maurelli, Martina, De Simone, Clara, Girolomoni, Giampiero, and Peris, Ketty

Subjects
Predicting factors identified patients with dupilumab who could benefit of dose spacing or treatment withdrawal
Abstract

Dupilumab is a monoclonal antibody against the IL-4/IL-13 receptor-subunit approved for the treatment of moderate-severe atopic dermatitis (AD). Some attempts to increase dose interval have been described in both trial and real-world settings. This study aimed to identify predictive clinical and demographic factors affecting patient selection for dose spacing or treatment withdrawal due to satisfactory response. This retrospective study included adult patients with moderate-to-severe AD treated with dupilumab for at least 16 weeks. Descriptive statistics were performed to analyze demographic and clinical variables. Logistic regression models were used to identify predictor variables. A total of 818 adult patients with moderate-to-severe AD was included in the study and 12% (97/818) of them performed dose spacing to 3–4 weeks or treatment withdrawal (8%, 67/818). The presence of non-cutaneous atopic manifestations (OR = 1.59, 95%CI = 1.06–2.38, p = 0.024), prurigo nodularis phenotype (OR = 4.5, 95%CI = 1.87–10.9, p = 0.001) and the age at treatment initiation (OR = 1.82, 95%CI = 1.12–2.94, p = 0.015) were confirmed as the strongest predictors of dose spacing or treatment withdrawal while maintaining dupilumab effectiveness. Our findings contribute to define the patient profile that could maintain the therapeutic response after dose spacing or treatment withdrawal. Predicting factors identified patients with dupilumab who could benefit of dose spacing or treatment withdrawal. Predicting factors identified patients with dupilumab who could benefit of dose spacing or treatment withdrawal.

Published
2023
Full Text
View/download PDF

27. Drug survival of methotrexate and predictor factors for discontinuation in psoriasis.

Author

Caldarola, Giacomo, De Luca, Eleonora, Mariani, Marco, Chiricozzi, Andrea, Peris, Ketty, and De Simone, Clara

Subjects
*SURVIVAL analysis (Biometry), *PSORIASIS, *METHOTREXATE, *TREATMENT duration, *DEMOGRAPHIC characteristics
Abstract

Background: Methotrexate (MTX) is a systemic therapy largely used for moderate‐severe psoriasis. There is a lack of data on its use in daily practice and particularly on its long‐term effectiveness and survival in psoriasis. Methods: We performed a single‐centered, retrospective, observational study to evaluate the drug survival of MTX in patients with psoriasis, treated in monotherapy with MTX between March 2015 and March 2022. Clinical and demographic characteristics were extracted from files of the patients. The drug survival was analyzed using Kaplan‐Meier survival curves, considering separately overall discontinuation, discontinuation due to MTX ineffectiveness, and discontinuation due to adverse events. Multivariable Cox regression analyses were carried out including clinically meaningful variables. Results: A total of 199 patients were included; 148 (74.4%) suspended MTX during the observation period. The reasons for discontinuation were adverse events (39.2%), ineffectiveness (38.5%), remission of psoriasis (12.2%), and other reasons (10.1%). Average duration of therapy was 10.1 months. Patients who remained on therapy after 1, 2, and 5 years of treatment were respectively 46.9, 35.6, and 29.3%. Positive predictive factors for therapy continuation were increasing age and the use of >15 mg of MTX for a period >3 months; the only negative predictive factor was the clinical variant of palmoplantar pustular. Conclusions: MTX is a valuable, cost‐effective option for long‐term treatment of psoriasis although drug survival is not comparable with that of biological treatments. Studies are needed to better understand the best dosing regimen to use, with the aim of achieving the best clinical outcomes and the lowest rate of side effects with this drug. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Risankizumab for the treatment of moderate‐to‐severe psoriasis: A multicenter, retrospective, 1 year real‐life study

Author

Caldarola, Giacomo, primary, Zangrilli, Arianna, additional, Bernardini, Nicoletta, additional, Bavetta, Mauro, additional, De Simone, Clara, additional, Graceffa, Dario, additional, Bonifati, Claudio, additional, Faleri, Sara, additional, Giordano, Domenico, additional, Mariani, Marco, additional, Micheli, Adriana, additional, Moretta, Gaia, additional, Pagnanelli, Gianluca, additional, Panasiti, Vincenzo, additional, Provini, Alessia, additional, Richetta, Antonio, additional, Peris, Ketty, additional, and Bianchi, Luca, additional

Published
2022
Full Text
View/download PDF

29. Tildrakizumab in moderate‐to‐severe plaque psoriasis: A multicenter, retrospective, real‐life study

Author

Caldarola, Giacomo, primary, Galluzzo, Marco, additional, Bernardini, Nicoletta, additional, Calabrese, Laura, additional, Grimaldi, Marta, additional, Moretta, Gaia, additional, Pagnanelli, Gianluca, additional, Shumak, Ruslana Gaeta, additional, Talamonti, Marina, additional, Tofani, Lorenzo, additional, Pallotta, Sabatino, additional, Peris, Ketty, additional, Potenza, Concetta, additional, De Simone, Clara, additional, and Campione, Elena, additional

Published
2022
Full Text
View/download PDF

34. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry

Author

Chiricozzi, Andrea, Talamonti, Marina, De Simone, Clara, Galluzzo, Marco, Gori, Niccolò, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iris, Lombardo, Maurizio, Feliciani, Claudio, Di Nardo, Lucia, Guarneri, Fabrizio, Peris, Ketty, Caldarola, Giacomo, Silvaggio, Dionisio, Dattola, Annunziata, Napolitano, Maddalena, Ferrucci, Silvia Mariel, Dal Bello, Giacomo, Bianchelli, Tommaso, Rovati, Chiara, Pigliacelli, Flavia, Ortoncelli, Michela, Hansel, Katharina, Calabrese, Giulia, Loi, Camilla, Iannone, Michela, Veronese, Federica, Romita, Paolo, Tronconi, Greta, Caroppo, Francesca, Tilotta, Giovanna, Sernicola, Alvise, Esposito, Maria, Raponi, Francesca, Gualdi, Giulio, Rech, Giulia, Musumeci, Maria Letizia, Nisticò, Steven Paul, Campitiello, Alessio, Bonzano, Laura, Piras, Viviana, Chiricozzi, A., Talamonti, M., De Simone, C., Galluzzo, M., Gori, N., Fabbrocini, G., Marzano, A. V., Girolomoni, G., Offidani, A., Rossi, M. T., Bianchi, L., Cristaudo, A., Fierro, M. T., Stingeni, L., Pellacani, G., Argenziano, G., Patrizi, A., Pigatto, P., Romanelli, M., Savoia, P., Rubegni, P., Foti, C., Milanesi, N., Belloni Fortina, A., Bongiorno, M. R., Grieco, T., Di Nuzzo, S., Fargnoli, M. C., Carugno, A., Motolese, A., Rongioletti, F., Amerio, P., Balestri, R., Potenza, C., Micali, G., Patruno, C., Zalaudek, I., Lombardo, M., Feliciani, C., Di Nardo, L., Guarneri, F., Peris, K., Caldarola, G., Silvaggio, D., Dattola, A., Napolitano, M., Ferrucci, S. M., Dal Bello, G., Bianchelli, T., Rovati, C., Pigliacelli, F., Ortoncelli, M., Hansel, K., Calabrese, G., Loi, C., Iannone, M., Veronese, F., Romita, P., Tronconi, G., Caroppo, F., Tilotta, G., Sernicola, A., Esposito, M., Raponi, F., Gualdi, G., Rech, G., Musumeci, M. L., Nistico, S. P., Campitiello, A., Bonzano, L., Piras, V., Chiricozzi, Andrea, Talamonti, Marina, De Simone, Clara, Galluzzo, Marco, Gori, Niccolò, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iri, Lombardo, Maurizio, Feliciani, Claudio, Di Nardo, Lucia, Guarneri, Fabrizio, Peris, Ketty, Caldarola, Giacomo, Silvaggio, Dionisio, Dattola, Annunziata, Napolitano, Maddalena, Ferrucci, Silvia Mariel, Dal Bello, Giacomo, Bianchelli, Tommaso, Rovati, Chiara, Pigliacelli, Flavia, Ortoncelli, Michela, Hansel, Katharina, Calabrese, Giulia, Loi, Camilla, Iannone, Michela, Veronese, Federica, Romita, Paolo, Tronconi, Greta, Caroppo, Francesca, Tilotta, Giovanna, Sernicola, Alvise, Esposito, Maria, Raponi, Francesca, Gualdi, Giulio, Rech, Giulia, Musumeci, Maria Letizia, Nisticò, Steven Paul, Campitiello, Alessio, Bonzano, Laura, Piras, Viviana, Chiricozzi, A, Talamonti, M, De Simone, C, Galluzzo, M, Gori, N, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Di Nardo, L, Guarneri, F, Peris, K, Caldarola, G, Silvaggio, D, Dattola, A, Napolitano, M, Ferrucci, S, Dal Bello, G, Bianchelli, T, Rovati, C, Pigliacelli, F, Ortoncelli, M, Hansel, K, Calabrese, G, Loi, C, Iannone, M, Veronese, F, Romita, P, Tronconi, G, Caroppo, F, Tilotta, G, Sernicola, A, Esposito, M, Raponi, F, Gualdi, G, Rech, G, Musumeci, M, Nistico, S, Campitiello, A, Bonzano, L, and Piras, V

Subjects
Registrie, 0301 basic medicine, Dermatitis, Systemic therapy, 0302 clinical medicine, Pandemic, Immunology and Allergy, Medicine, Registries, atopic dermatitis, COVID, SARS‐ CoV, treatment, SARS-CoV, Atopic dermatitis, Dupilumab, Italy, Original Article, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Human, atopic dermatiti, Adult, medicine.medical_specialty, Teledermatology, SARS‐CoV, atopic dermatitis, treatment, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Immunology, Communicable Disease Control, Humans, Pandemics, SARS-CoV-2, COVID-19, Dermatitis, Atopic, Atopic, 03 medical and health sciences, Settore MED/35, Disease severity, Internal medicine, business.industry, medicine.disease, 030104 developmental biology, 030228 respiratory system, atopic dermatitis, COVID, SARS-CoV, business
Abstract

Background Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID‐19) pandemic. Methods A national registry, named DA‐COVID‐19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID‐19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID‐19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician‐ and patient‐reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. Results A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS‐CoV‐2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS‐CoV‐2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID‐related death occurred. Conclusions Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab‐treated patients., Among 1831 studied AD patients, 86.1% were treated with dupilumab. Patients continuing therapy experienced a marked reduction of disease severity during pandemic. The causes of treatment interruption included: fear of increased susceptibility to SARS‐CoV‐2 infection (24.8%), occurrence of comorbidities (5.9%), age above 60 years (5.2%), SARS‐CoV‐2 infection (2.8%), close contact with SARS‐CoV‐2‐positive subject (2.4%), other reasons, for example, inability to maintain drug supply, non‐medical/unspecified causes (58.7%).

Published
2021

35. Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study

Author

Caldarola, Giacomo, Chiricozzi, A, Megna, M, Dapavo, P, Giunta, A, Burlando, M, Malagoli, P, Dini, V, Mariani, M, Fabbrocini, G, Quaglino, P, Bianchi, L, Parodi, A, Peris, K, and De Simone, C

Abstract

ABSTRACTBackgroundConfirmatory data on the long-term effectiveness and safety of ixekizumab in psoriatic patients from real-world studies are needed.ObjectivesThe primary aim was to evaluate the 3-year drug survival of ixekizumab in the treatment of patients with moderate-to-severe plaque psoriasis, in a multicenter real‐world setting. The secondary aim was to assess the influence of predictive factors on the drug survival of ixekizumab.MethodsA retrospective analysis was performed on a cohort of patients with chronic plaque psoriasis, who received at least one dose of ixekizumab before December 2018. The drug survival analysis was performed and descriptively analyzed using Kaplan–Meier survival curves. Multivariable Cox regression analyses were carried out including variables considered to be of clinical importance.ResultsA total of 306 patients were enrolled. The overall drug survival at 12, 24, and 36 months of treatment with ixekizumab was 92.11%, 83.85%, and 80.19%, respectively. A higher probability (HR 2.34) of drug withdrawal was found among patients who had already received an anti-IL-17 agent compared with bio-naive patients (p 0.017).ConclusionsWe found that ixekizumab is a biological agent characterized by long-term effectiveness, not influenced by several clinical factors and associated with a good safety profile.

Published
2023
Full Text
View/download PDF

39. Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy

Author

Zangrilli, Arianna, primary, Caldarola, Giacomo, additional, Bernardini, Nicoletta, additional, Bavetta, Mauro, additional, Graceffa, Dario, additional, Bonifati, Claudio, additional, Cantoresi, Franca, additional, Faleri, Sara, additional, Giordano, Domenico, additional, Mariani, Marco, additional, Micheli, Adriana, additional, Moretta, Gaia, additional, Pirro, Federico, additional, Pagnanelli, Gianluca, additional, Panasiti, Vincenzo, additional, Provini, Alessia, additional, Richetta, Antonio, additional, Sacchelli, Lidia, additional, Bianchi, Luca, additional, and Peris, Ketty, additional

Published
2021
Full Text
View/download PDF

41. Therapeutic Impact and Management of Persistent Head and Neck Atopic Dermatitis in Dupilumab-Treated Patients.

Author

Chiricozzi, Andrea, Gori, Niccolò, Di Nardo, Lucia, Antonelli, Flaminia, Caruso, Cristiano, Caldarola, Giacomo, Calabrese, Laura, Guerriero, Cristina, De Simone, Clara, and Peris, Ketty

Subjects
ATOPIC dermatitis, NECK, HEAD, CUTANEOUS manifestations of general diseases, DUPILUMAB
Abstract

Background: Localization of atopic dermatitis (AD) in exposed areas such as the hands, head, and neck has been considered as a negative factor impacting on dupilumab response, although a comparison of exposed versus unexposed areas is not currently available. Objectives: The aim of this study is to evaluate the clinical response to dupilumab depending on the presence or persistency of AD skin manifestations in specific body areas. Methods: The study retrospectively collected clinical and demographic data of adult patients affected by moderate to severe AD. Based on the anatomical sites involved, 5 subcohorts of patients were identified. Results: A total of 41 patients were included in the study. Disease amelioration was detected during the study period, although baseline head/neck and hand localization was associated with a significantly lower likelihood of achieving an Eczema Area Severity Index (EASI) ≤1. In addition, patients with head/neck persistency showed a significantly lower response when compared to patients without persistency of head/neck AD in terms of both mean EASI and Dermatology Life Quality Index (DLQI) reduction. Conclusion: AD localization in exposed areas at the baseline and AD persistency at the head/neck may have a negative impact on certain treatment response parameters to dupilumab therapy. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies.

Author

Pirro, Federico, Caldarola, Giacomo, Chiricozzi, Andrea, Tambone, Sara, Mariani, Marco, Calabrese, Laura, D'Urso, Dario Francesco, De Simone, Clara, and Peris, Ketty

Subjects
*COVID-19 pandemic, *BIOTHERAPY, *SARS-CoV-2, *TELEPHONE surveys, *COVID-19, *PSORIATIC arthritis
Abstract

The beginning of 2020 has been marked by COVID-19 pandemic, with a strong impact on several national health systems worldwide. To describe the impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biologics. A telephone survey was conducted in May 4–10 2020 about the Italian lockdown period (March 9–May 3 2020) in a cohort of psoriatic patients treated with biologics, asking about any exposure to COVID-19, disease status, continuation of therapy, work activity and psychological status through Hospital Anxiety and Depression Scale (HADS), Perceived Stress Scale (PSS) and Brief Resilience Scale (BRS). 226 patients were interviewed, with no COVID-19 positive cases. Sixty-three of 226 (27.9%) described worsening of the disease with a correlation to drug withdrawal [43/226 (19%)]. Correlation was also found between the worsening of psoriasis and HADS anxiety, HADS depression, BRS and PSS abnormal scores considered both as categorical and continuous variables. No correlation was found between worsening of psoriasis and work activity. Uncertainty about whether biologics could increase the risk of SARS-CoV-2 infection led to drug withdrawal with subsequent worsening of psoriasis. Moreover, psychological status also had a direct influence on the clinical course of the disease. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results